undamentalytics Newsletter
Sign in

Charles River Laboratories (CRL) stock

Add to watchlist

Add holding +

NYSE: CRL NYSE Life Sciences Tools & Services Next results ~November 4, 2026

C+ Fundamentals grade

Charles River Laboratories is a non-clinical drug development partner whose work spans the research process from target identification through regulatory safety testing. Its core offering began with supplying purpose-bred research models, chiefly rodents, of which it maintains over 140 stocks and strains, alongside discovery services, regulated and non-regulated safety assessment studies, and testing and manufacturing products.

Customers include pharmaceutical and biotechnology firms, agricultural, industrial chemical, medical device, diagnostic and consumer product companies, contract research and manufacturing organisations, hospitals, universities and government agencies. The company earns money by selling research models, charging for outsourced discovery and safety studies, and supplying branded quality-control products and services such as Endosafe endotoxin testing, Celsis microbial detection and Accugenix identification, as well as contract development and manufacturing for cell and gene therapies.

The business runs through three reportable segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. It operates across more than 120 sites in over 20 countries, with production centres on three continents. Founded in 1947 and headquartered in Wilmington, Massachusetts, it has provided research models for over 75 years.

Based on Charles River Laboratories's 10-K filed February 18, 2026.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$120

Cash-flow model

Base case. Range ~$73–$170 across our lower- and higher-growth cases (-3%–7% a year).

Price vs value

Overvalued

The price is above our entire value range; our base value is 66% below it.

Price used: $338.54, November 2, 2026

Charles River Laboratories valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 6 selling2 purchases and 21 sales by directors and officers, last 12 monthsInsider trades
  • Funds266 adding, 262 cuttingOf 68 active managers that changed their stake, 29 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Charles River Laboratories files

Where Charles River Laboratories stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $4.00bn, down 0.7% on a year earlier, slower than 0.1% a quarter earlier. That puts it 9 of 9 for growth among the life sciences tools & services companies we cover. Free-cash-flow margin fell to 9.3% from 14.4% a year earlier. The diluted share count is down 3.9% on a year earlier, which lifts each remaining share. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 1 of our 3 financial-health checks. Our cash-flow model value is $108 a share, against a share price of $316. At that price, our model says the market is pricing in about 18.4% a year of cash-flow growth for five years, faster than the 2.5% a year revenue growth it has delivered.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Charles River Laboratories's trailing-twelve-month revenue fell 0.7% year on year, with a free-cash-flow margin of 9.3%. Where it stands out: change in share count of -3.9% ranks 3 of 46 life sciences tools & services companies we cover. Where it lags: revenue growth of -0.7% ranks 44 of 54 life sciences tools & services companies we cover.

Our discounted-cash-flow model values the business at ~$120 per share in the base case (~$73–$170 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 35.9% while net income fell 255.7%: a 220pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Shrinking share count. Diluted shares fell 3.9% in a year, so each share owns more of the business.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Priced above our value. The share price of $338.54 is 66% above our value per share of $120.
  • Revenue shrinking. Revenue fell 0.7% over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 46% and a beta of 1.3 against the S&P 500.
  • Short interest rising. Shares sold short rose 27% in a month to 6.9% of tradable shares.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
$3.02 against an average estimate of $2.74: beat by 10.3%
Revenue
$1.00bn, down 2.7% on a year earlier
Share reaction
+13.4% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Guidance given
revenue growth/(decrease), reported growth -3.5% to -2.5% (2026); revenue growth/(decrease), organic growth 0% to 1% (2026)
Next report
November 4, 2026; average EPS estimate $2.97

Charles River Laboratories' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-5.8%
  • 1 week-5.2%
  • 1 month+16.7%
  • This year+69.7%
  • 1 year+88.0%
  • 5 years-12.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$4B
Operating margin
2.3%
Net margin
-6.0%
EPS (TTM, diluted)
$-4.89

Growth

Revenue growth
−0.7%
Change in growth rate
−0.8 pts
Share count change
−3.9%

Cash

Free cash flow (TTM)
$371M
FCF margin
9.3%
Stock pay % of revenue
2.1%

Earnings

Last results
August 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Insider trade
  2. Announcement
  3. Insider trade
  4. Insider trade
  5. Insider trade
  6. Insider trade
  7. Insider trade
  8. Insider trade
  9. Results
  10. Guidance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Charles River Laboratories valuation models and calculator

What the price is pricing in

The share price implies about 17.1% a year of cash-flow growth for five years.That is faster than the 2.5% a year revenue growth Charles River Laboratories has delivered.

  • Priced in17.1%
  • Last 12 months-0.7%
  • 3 years a year-1.5%
  • 5 years a year2.5%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($347.57, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Sell12-month view
12-month price target
~$120
Price used
$347.57close November 3, 2026
Implied change
▼ 67%
Uncertainty
High

How we got here: a discounted-cash-flow model of Charles River Laboratories's free cash flow after stock-based pay with after-tax interest added back ($493M, FY2026 Q2 TTM), growing -0.2% and 2.2% in the next two years (forecasts, guidance and its record), then back to 2% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$73–~$170 ; that spread sets a 35% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Charles River Laboratories's free cash flow after stock-based pay ( $493M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Charles River Laboratories as an operating company, with every model that fits that kind of business. Cost of equity 9.8%: the 10-year Treasury yield (4.9%) plus a beta of 1.08 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$120 ~$73–$170 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$290 ~$230–$410 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$42 ~$28–$65 Left out: out of range vs price (0.13x)
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$39 ~$34–$45 Left out: out of range vs price (0.11x)
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$170 ~$120–$290 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Charles River Laboratories with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −38%
  • Revenue growth 5 points higher ▲ +50%
  • Free-cash-flow margin 1 point lower ▼ −13%
  • Last year's free-cash-flow margin change, if it persists ▼ −40%
  • Discount rate 1 point higher ▼ −21%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $96$149$220$313$434$591
8.5% $61$100$151$217$304$415
10% $40$70$109$160$226$310

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$80.08$76.19$109.45$111.72$151.93$251.71$369.20$217.90$236.40$186.16$203.66$338.54
Market value$3.8bn$3.7bn$5.3bn$5.5bn$7.5bn$12.7bn$19.0bn$11.2bn$12.2bn$9.6bn$10.1bn$16.5bn
+ Net debt (− = net cash)$745m$1.1bn$981m$1.5bn$1.7bn$1.8bn$2.4bn$2.5bn$2.4bn$2.0bn$1.9bn$2.4bn
Enterprise value$4.6bn$4.8bn$6.3bn$6.9bn$9.2bn$14.5bn$21.4bn$13.7bn$14.5bn$11.7bn$12.0bn$18.9bn
Multiples
Price / sales 2.8x2.2x2.9x2.4x2.9x4.4x5.4x2.8x2.9x2.4x2.5x4.1x
Price / earnings 25.5x23.6x43.1x24.2x30.0x35.0x48.6x23.0x25.6xn/m——
Price / free cash flow 15.7x14.0x22.6x18.2x22.2x33.5x35.7x37.9x33.3x19.2x19.5x44.5x
EV / EBITDA 15.1x13.1x15.0x14.1x16.8x21.7x25.0x14.3x15.6x19.8x28.1x48.8x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

60 /100

Moderate moat

How hard Charles River Laboratories's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 12 / 20

    Cash operating profit has been a median 9.8% of total assets over 8 years.

  • Pricing power 13 / 20

    Gross margin has been a median 36.9%, moving by 1.5 percentage points (standard deviation) across 8 years.

  • Durability 6 / 20

    Operating margin has been a median 13.9%; its worst year was 2.3%.

  • Cash conversion 16 / 20

    Free cash flow was positive in 10 of 10 years, at a median 12.6% of revenue.

  • Discipline 18 / 20

    The diluted share count fell 4.7% over five years; stock-based pay has been a median 1.9% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (65 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, before the open. Analysts expect revenue of $960m and EPS of $2.97 (range $2.93 to $3.09) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $11.38 +11% $3.9bn −3%
Next $12.75 +12% $4.0bn +3%

Next year's EPS estimate has moved +3.4% in 90 days, across 17 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +2.5% on 90 days ago. In the last 30 days, 5 analysts raised Charles River Laboratories's forecast and 3 cut it.

Consensus EPS forecast Charles River Laboratories, last 90 days
$11.00 $11.50 $12.00 $12.50 $13.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $11.10 Current fiscal year, 60 days ago: $11.32 Current fiscal year, 30 days ago: $11.33 Current fiscal year, 7 days ago: $11.38 Current fiscal year, Now: $11.38 $11.38 Next fiscal year, 90 days ago: $12.33 Next fiscal year, 60 days ago: $12.69 Next fiscal year, 30 days ago: $12.71 Next fiscal year, 7 days ago: $12.76 Next fiscal year, Now: $12.75 $12.75

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $11.10$12.33
60 days ago $11.32$12.69
30 days ago $11.33$12.71
7 days ago $11.38$12.76
Now $11.38$12.75

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $2.74 $3.02 +10.3%
Mar 2026 $1.95 $2.06 +5.4%
Dec 2025 $2.35 $2.39 +1.9%
Sept 2025 $2.34 $2.43 +3.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 5, 2026
  • Revenue growth/(decrease), reported 2026 -3.5% growth to -2.5% growth Raised
    “Revenue growth/(decrease), reported (3.5)% - (2.5)%” source
  • Revenue growth/(decrease), organic 2026 0% growth to 1% growth Raised
    “Revenue growth/(decrease), organic (1) 0.0% - 1.0% (1.5)% - (0.5)%” source
  • GAAP EPS estimate 2026 $3.05 to $3.35 GAAP Lowered
    “GAAP EPS estimate $3.05 - $3.35” source
  • Non-GAAP EPS estimate 2026 $11.15 to $11.45 Non-GAAP Raised
    “Non-GAAP EPS estimate $11.15 - $11.45” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Charles River Laboratories's revenue by -0.2% next year and +2.2% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (-0.9%, weight 56%) , management guidance (-1.4%, weight 19%) and the company's own record (+2.0%, weight 25%) . How the weights are set.

Analyst recommendations

17 analysts, Oct 2026
Buy1482%
Hold212%
Sell16%

Monthly trend

  1. Oct 2026311217
  2. Sep 2026411218
  3. Aug 202649216
  4. Jul 202639316

Counts of recommendations published by analysts covering Charles River Laboratories, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
6.9%
of tradable shares
Days to cover
2.77
at average volume
Short interest, 1 month
+27%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
0.5%
of shares
Employees
18,300
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +88.0%

$180.07 on October 31, 2025 to $338.54

ThenNowEffect
Revenue (last 12 months) $4.0bn $4.0bn −0.7%
P/S multiple 2.3x 4.1x +82.0%
Share count 51m 49m +4.1%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +86.1%

$181.91 on November 3, 2023 to $338.54

ThenNowEffect
Revenue (last 12 months) $4.2bn $4.0bn −4.3%
P/S multiple 2.2x 4.1x +84.6%
Share count 51m 49m +5.3%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CRL+51%−42%+9%−22%+8%+70%
Industry peers (median)+4%−53%−3%−13%−7%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CRL83%25%42%33%50%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CRL−23%−52%−37%−35%−48%−34%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 78% from September 24, 2021 to April 11, 2025. Getting back needed a 359% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$149.93 – $376.10
From 52-week high
−10.0%
vs 50-day average
+11.8%
vs 200-day average
+52.3%
Volatility (1 year)
46%
Beta vs S&P 500
1.33

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±8.3%
After a week
7 up, 5 down
typical move ±10.2%
After a month
7 up, 5 down
typical move ±11.9%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 +13.4% −0.4% +21.5% +25.3%
May 7, 2026 −2.3% +0.5% −12.4% +2.6%
February 18, 2026 +3.6% +0.2% +5.7% −3.5%
January 13, 2026 −1.1% −0.7% +3.6% −27.5%
November 5, 2025 −3.9% −0.7% −3.6% +3.6%
August 6, 2025 −10.6% +0.7% −7.5% −2.1%
May 7, 2025 +22.5% +1.1% +20.4% +25.4%
February 19, 2025 +5.1% −0.2% +8.8% +7.1%
November 6, 2024 +11.5% +3.3% +9.5% +1.7%
August 7, 2024 −11.7% +1.6% −13.2% −17.8%
May 9, 2024 −3.0% +0.7% −4.5% −8.8%
February 14, 2024 +11.4% +1.6% +12.1% +17.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Charles River Laboratories’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Implied vs realised volatility

Options look rich

Option prices imply clearly more movement than the shares have shown. That strengthens the case for selling options.

  • Implied is 1.46× the last 60 days’ realised volatility , richer than 89% of the 229 stocks we screen today.
  • Puts and calls are priced at about the same implied volatility.
  • Why: implied is 1.46x 60-day realised, above 1-year realised, and in the top 20% of our coverage today.

Our rule for “rich”: implied at least 1.2× 60-day realised (beyond measurement noise), above 1-year realised (not just a calm spell), and in the top 20% of our coverage that day. Never with results inside the option’s life. These are our conventions, built on research showing option prices usually imply more movement than follows, most when the gap is wide. How we judge this.

Cash-secured put

Not offered: rated Sell.

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

CRL Charles River Laboratories Grade C+ $342.23

Own 100 shares, sell the $350 call expiring December 18, 2026 (46 days) for $22.80 a share — $2,280 per contract.

Previous session · Bid $22.80, ask $24.30, quoted Mon 2 Nov, 17:19 New York time with CRL at $342.23. Option prices move with the shares: check the live chain at your broker before trading.

  • If CRL ends below $350: you keep your shares and the $2,280 — 6.7% extra on the position, 52.9% a year at that pace.
  • If it ends above $350: your shares are sold at $350, a total return of 8.9% including the premium — at or above our value of ~$120.
$3.1k $0 −$6.4k Break-even $319.43 Price $342.23 ← Our value ~$120
Profit or loss per contract at expiry, by share price (including the shares bought at today's price).
Premium
$2,280
Annualised
52.9%
Break-even
$319.43
Max gain
$3,057
Chance of selling
~51%

Results are expected around October 28, 2026, before this option expires: the share price can jump on results, and the premium partly reflects that.

Collar

Own the shares, buy the $310 put and sell the $350 call, both expiring December 18, 2026 (46 days).

  • Net credit of $7.10 a share ($710 per contract of 100 shares).
  • Worst case at expiry: -7.3%, if the shares fall below $310 (-9.4% from today).
  • Best case at expiry: +4.3%, if the shares rise above $350 (+2.3%); gains beyond that go to the call buyer.

Offered because the shares trade at or above our fair value of $120: a way to hold on with a floor under the price, paid for by giving up upside the model does not expect. Strikes near 25-delta; the put at its ask and the call at its bid. Protection has a cost over time: research on protective puts finds they have usually lowered returns.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Charles River Laboratories in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Charles River Laboratories
$3.9B $4B $4.1B $4.2B $4.3B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $4.2B Revenue (TTM), FY23 Q4: $4.1B Revenue (TTM), FY24 Q1: $4.1B Revenue (TTM), FY24 Q2: $4.1B Revenue (TTM), FY24 Q3: $4.1B Revenue (TTM), FY24 Q4: $4B Revenue (TTM), FY25 Q1: $4B Revenue (TTM), FY25 Q2: $4B Revenue (TTM), FY25 Q3: $4B Revenue (TTM), FY25 Q4: $4B Revenue (TTM), FY26 Q1: $4B Revenue (TTM), FY26 Q2: $4B $4B

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $4.2B
FY23 Q4 $4.1B
FY24 Q1 $4.1B
FY24 Q2 $4.1B
FY24 Q3 $4.1B
FY24 Q4 $4B
FY25 Q1 $4B
FY25 Q2 $4B
FY25 Q3 $4B
FY25 Q4 $4B
FY26 Q1 $4B
FY26 Q2 $4B
Revenue growth, TTM YoY Charles River Laboratories
-5% 0% 5% 10% 15% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 11.5% Revenue growth, TTM YoY, FY23 Q4: 3.9% Revenue growth, TTM YoY, FY24 Q1: 0.5% Revenue growth, TTM YoY, FY24 Q2: -2.4% Revenue growth, TTM YoY, FY24 Q3: -3.7% Revenue growth, TTM YoY, FY24 Q4: -1.9% Revenue growth, TTM YoY, FY25 Q1: -2.2% Revenue growth, TTM YoY, FY25 Q2: -1.2% Revenue growth, TTM YoY, FY25 Q3: -0.9% Revenue growth, TTM YoY, FY25 Q4: -0.9% Revenue growth, TTM YoY, FY26 Q1: 0.1% Revenue growth, TTM YoY, FY26 Q2: -0.7% -0.7%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 11.5%
FY23 Q4 3.9%
FY24 Q1 0.5%
FY24 Q2 -2.4%
FY24 Q3 -3.7%
FY24 Q4 -1.9%
FY25 Q1 -2.2%
FY25 Q2 -1.2%
FY25 Q3 -0.9%
FY25 Q4 -0.9%
FY26 Q1 0.1%
FY26 Q2 -0.7%
Operating margin (TTM) Charles River Laboratories
0% 5% 10% 15% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 15.4% Operating margin (TTM), FY23 Q4: 14.9% Operating margin (TTM), FY24 Q1: 14.0% Operating margin (TTM), FY24 Q2: 13.8% Operating margin (TTM), FY24 Q3: 13.0% Operating margin (TTM), FY24 Q4: 5.6% Operating margin (TTM), FY25 Q1: 4.4% Operating margin (TTM), FY25 Q2: 3.1% Operating margin (TTM), FY25 Q3: 3.5% Operating margin (TTM), FY25 Q4: 0.6% Operating margin (TTM), FY26 Q1: 1.7% Operating margin (TTM), FY26 Q2: 2.3% 2.3%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 15.4%
FY23 Q4 14.9%
FY24 Q1 14.0%
FY24 Q2 13.8%
FY24 Q3 13.0%
FY24 Q4 5.6%
FY25 Q1 4.4%
FY25 Q2 3.1%
FY25 Q3 3.5%
FY25 Q4 0.6%
FY26 Q1 1.7%
FY26 Q2 2.3%
FCF margin (TTM) Charles River Laboratories
8% 10% 12% 14% 16% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 8.7% FCF margin (TTM), FY23 Q4: 8.8% FCF margin (TTM), FY24 Q1: 10.1% FCF margin (TTM), FY24 Q2: 11.9% FCF margin (TTM), FY24 Q3: 13.8% FCF margin (TTM), FY24 Q4: 12.4% FCF margin (TTM), FY25 Q1: 14.0% FCF margin (TTM), FY25 Q2: 14.4% FCF margin (TTM), FY25 Q3: 13.5% FCF margin (TTM), FY25 Q4: 12.9% FCF margin (TTM), FY26 Q1: 9.7% FCF margin (TTM), FY26 Q2: 9.3% 9.3%

Source: SEC EDGAR filings. Retrieved October 20, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 8.7%
FY23 Q4 8.8%
FY24 Q1 10.1%
FY24 Q2 11.9%
FY24 Q3 13.8%
FY24 Q4 12.4%
FY25 Q1 14.0%
FY25 Q2 14.4%
FY25 Q3 13.5%
FY25 Q4 12.9%
FY26 Q1 9.7%
FY26 Q2 9.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 1,172 1,133 1,143 1,130 1,166 1,298 1,363 1,681 1,858 2,266 2,621 2,924 3,540 3,976 4,129 4,050 4,015 3,999
EBITDA 260 −205 260 247 248 274 301 364 419 493 549 668 855 955 931 589 428 388
Operating income 170 −299 174 166 151 178 206 238 288 331 351 433 590 651 617 227 25 90
Net income 114 −337 110 97 103 127 149 155 123 226 252 364 391 486 475 22 −144 −238
Diluted EPS $1.74 −$5.38 $2.14 $2.01 $2.12 $2.66 $3.13 $3.23 $2.54 $4.62 $5.07 $7.20 $7.60 $9.48 $9.22 $0.20 −$2.91 −$4.89
Growth (year on year)
Revenue −9.5% −3.3% +0.8% −1.1% +3.2% +11.3% +5.1% +23.3% +10.5% +22.0% +15.7% +11.5% +21.1% +12.3% +3.9% −1.9% −0.9% −0.7%
EBITDA — −178.9% — −4.8% +0.4% +10.5% +9.9% +20.9% +15.2% +17.6% +11.4% +21.6% +28.1% +11.6% −2.5% −36.8% −27.3% −30.0%
Operating income — −276.0% — −4.9% −8.7% +17.4% +16.2% +15.1% +21.4% +15.0% +6.0% +23.2% +36.3% +10.4% −5.2% −63.2% −88.9% −27.6%
Net income — −394.2% — −11.2% +5.7% +23.2% +17.8% +3.7% −20.3% +83.5% +11.3% +44.6% +7.3% +24.4% −2.4% −95.3% — —
Diluted EPS — −409.2% — −6.1% +5.5% +25.5% +17.7% +3.2% −21.4% +81.9% +9.7% +42.0% +5.6% +24.7% −2.7% −97.8% — —
Margins
EBITDA margin 22.2% −18.1% 22.7% 21.9% 21.3% 21.1% 22.1% 21.7% 22.6% 21.8% 21.0% 22.8% 24.2% 24.0% 22.6% 14.5% 10.7% 9.7%
Operating margin 14.5% −26.3% 15.3% 14.7% 13.0% 13.7% 15.1% 14.1% 15.5% 14.6% 13.4% 14.8% 16.7% 16.4% 14.9% 5.6% 0.6% 2.3%
Net margin 9.8% −29.7% 9.6% 8.6% 8.8% 9.8% 11.0% 9.2% 6.6% 10.0% 9.6% 12.5% 11.0% 12.2% 11.5% 0.5% −3.6% −6.0%
Free-cash-flow margin 11.6% 11.1% 13.8% 14.2% 14.6% 15.0% 17.9% 15.6% 12.7% 13.3% 13.0% 13.0% 15.0% 7.4% 8.8% 12.4% 12.9% 9.3%
Cash flow
Cash from operations 216 168 207 208 209 252 307 317 318 441 481 547 761 620 684 735 738 582
Capital spending 80 43 49 48 39 57 63 55 82 140 141 167 229 325 319 233 219 212
Free cash flow 136 125 158 160 170 195 244 262 236 301 340 380 532 295 365 502 518 371
Stock-based pay 24 26 22 22 25 31 40 44 44 47 57 56 71 74 72 70 71 83
Free cash flow after stock pay 112 100 136 139 145 164 203 218 192 254 283 324 461 221 293 432 447 288
Balance sheet
Cash 183 179 69 110 156 160 118 118 164 195 238 228 241 234 277 195 214 192
Total debt 493 701 739 673 664 772 863 1,235 1,145 1,668 1,888 1,980 2,666 2,711 2,653 2,243 2,140 2,627
Net debt (negative = net cash) 310 522 671 563 508 612 745 1,117 981 1,473 1,650 1,751 2,425 2,477 2,376 2,049 1,926 2,435
Diluted shares 66m 63m 51m 48m 48m 48m 48m 48m 49m 49m 50m 51m 51m 51m 51m 52m 50m 49m
Returned to shareholders
Buybacks 46 357 284 64 166 122 117 12 107 14 18 24 41 39 24 119 361 324
Total returned 46 357 284 64 166 122 117 12 107 14 18 24 41 39 24 119 361 324

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 7 checks passed · June 27, 2026
What it owns · $7.5bn
Short-term assets $1.5bnLonger-term assets $6.0bn
What it owes, and who funded it · $7.5bn
Short-term liabilities $1.1bnLonger-term liabilities $3.5bnShareholders' equity $2.8bn
  • Short-term assets cover short-term liabilities $1.5bn of assets due within a year against $1.1bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.5bn short-term assets against $3.5bn of longer-dated liabilities.
  • More cash than debt $192m of cash against $2.6bn of debt.
  • Debt below 40% of shareholders' equity Debt is 92% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 105% to 92% over five years.
  • A year's operating cash flow covers at least 20% of debt $582m of operating cash flow against $2.6bn of debt.
  • Operating profit covers interest at least five times over Operating income of $90m against $106m of interest.

From Charles River Laboratories's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
$324M
Returned to shareholders
87%
of free cash flow
Buybacks, last 3 fiscal years
$504M
Diluted share count
−3.9%
year over year
Total shareholder yield
2.0%
dividends 0.0% + buybacks 2.0% of market value
Sales & admin spending
19.1%
of revenue
Days sales outstanding
65 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated CRL MTD ILMN BRKR WAT MEDP Median
Revenue, last 12 months $4.0bn $4.1bn $4.5bn $3.5bn $4.6bn $2.8bn $229m
Revenue growth, last 12 months −0.7% 6.9% 5.8% 1.6% 52.5% 20.4% 6.9%
Revenue growth, 3-year average −1.5% 1.5% 0.5% 8.8% 15.8% 16.8% 2.9%
Revenue growth, latest quarter −2.7% 4.5% 4.2% 5.2% 113.3% 8.5% 8.5%
Gross margin 36.7% 60.3% 67.9% 46.4% 59.3% — 51.9%
Operating margin 2.3% — 21.2% −0.9% 7.1% 21.4% −14.3%
Operating margin, 3-year average 6.4% — 4.2% 5.1% 20.5% 20.9% −22.4%
Net margin −6.0% 21.9% 19.7% −2.0% 3.6% 18.2% −16.1%
Cash from operations / revenue 14.6% 23.6% 27.1% 5.4% 11.8% 25.5% 1.3%
Free-cash-flow margin 9.3% 20.9% 23.3% 2.7% 9.4% 23.5% −2.2%
Free-cash-flow margin, 3-year average 11.9% 22.3% 19.7% 3.2% 17.5% 26.0% 0.6%
Stock pay / revenue 2.1% 0.6% 5.9% 0.6% 1.6% 0.8% 4.4%
Change in share count −3.9% −3.0% −2.1% −2.0% 25.7% −5.1% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth -0.7% 6.9% 44 of 54
Change in growth rate Growth -0.8pp +0.4pp 37 of 54
Operating margin Profitability 2.3% -14.3% 15 of 52
Net margin Profitability -6.0% -12.2% 24 of 54
Free-cash-flow margin Cash generation 9.3% -1.3% 17 of 54
Stock pay as % of revenue Cash generation 2.1% 4.4% 15 of 53
Long-term debt as % of assets Balance sheet 34.8% 26.3% 25 of 35
Change in share count Balance sheet -3.9% 1.0% 3 of 46
Days sales outstanding Balance sheet 65 days 62 days 29 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 27, 2025
Segments
Line of business Revenue Share YoY
Discovery and Safety Assessment $2.4B 59.8% ▼ 2.0%
Research Models and Services $846M 21.1% ▲ 2.0%
Manufacturing Support $766M 19.1% ▼ 0.4%
Products and services
Line of business Revenue Share YoY
Services $3.3B 80.9% ▼ 1.6%
Products $765M 19.1% ▲ 2.6%
Geography
Region Revenue Share YoY
United States $2.1B 53.3% ▼ 4.4%
Europe $1.1B 27.5% ▲ 2.3%
Canada $501M 12.5% ▲ 3.9%
Asia Pacific $205M 5.1% ▲ 4.1%
Other $64.9M 1.6% ▲ 22.8%

From Charles River Laboratories's 10-K filed February 18, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$12.9B
Institutions reporting
567
Shares held vs prior quarter
▼ 1.4%
Positions opened / closed
71 / 60

Top buyers and sellers, Q2 2026: 266 institutions bought and 262 sold ; the biggest buyer was FMR LLC (+784K shares) and the biggest seller Mackenzie Financial Corp (−593K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
FMR LLC $962M 4.2M 7.5% ▲ 22.7%
Blackrock, Inc. $861M 3.8M 6.7% ▼ 1.6%
Vanguard Capital Management LLC $714M 3.1M 5.5% ▼ 1.7%
Invesco Ltd. $677M 3.0M 5.3% ▲ 24.5%
Harris Associates L P $508M 2.2M 3.9% ▲ 4.1%
Vanguard Portfolio Management LLC $501M 2.2M 3.9% ▼ 3.6%
Allspring Global Investments Holdings, LLC $436M 1.9M 3.4% ▼ 4.4%
State Street Corp $423M 1.9M 3.3% ▼ 0.5%
Dimensional Fund Advisors LP $374M 1.6M 2.9% ▼ 0.2%
Ariel Investments, LLC $342M 1.5M 2.7% ▲ 4.3%
Price T Rowe Associates Inc $341M 1.5M 2.7% ▲ 33.8%
Geode Capital Management, LLC $296M 1.3M 2.3% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Charles River Laboratories's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $7,338 2 trades by 2 insiders, last 12 months Insider sales History → $52.1M 21 trades by 6 insiders · 94% under pre-set plans
Net ▼ $52.1M net selling
Insider Date Trade Shares Price Value
Foster James C Director October 22, 2026 Sell pre-set plan 24,042 $350.00 $8.4M
Parisotto Shannon M CEVP, Disc & Safety Assessment October 21, 2026 Sell pre-set plan 2,156 $344.41 $742,548
Parisotto Shannon M CEVP, Disc & Safety Assessment October 5, 2026 Sell pre-set plan 981 $308.44 $302,580
Coleman Glenn EVP & Chief Financial Officer September 30, 2026 Buy 10 $297.43 $2,974
Foster James C Director August 25, 2026 Sell pre-set plan 33,561 $300.00 $10.1M
Parisotto Shannon M CEVP, Disc & Safety Assessment August 19, 2026 Sell pre-set plan 2,039 $294.12 $599,711
Andrews Nancy C Director August 18, 2026 Sell 573 $285.24 $163,443
Parisotto Shannon M CEVP, Disc & Safety Assessment August 11, 2026 Sell pre-set plan 3,714 $279.66 $1M
Girshick Birgit Chief Executive Officer August 11, 2026 Sell pre-set plan 6,500 $279.90 $1.8M
Foster James C Director August 10, 2026 Sell pre-set plan 28,733 $275.00 $7.9M
Creamer Victoria L EVP & Chief People Officer August 6, 2026 Sell 4,179 $259.16 $1.1M
Knell Michael Gunnar SVP, Finance and CAO August 6, 2026 Sell 736 $258.53 $190,278

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 20 trades and filings

No trades in Charles River Laboratories disclosed in the last 12 months; 20 earlier trades on record.

  • Robert P. Bresnahan, Jr.(R-PA 8):Sale (full), $1,001 - $15,000, traded May 15, 2025, filed May 31, 2025
  • Jefferson Shreve(R-IN 6):Sale (full), $15,001 - $50,000, traded May 12, 2025, filed June 22, 2025
  • Jefferson Shreve(R-IN 6):Purchase, $15,001 - $50,000, traded May 8, 2025, filed June 22, 2025

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around October 28, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 7, 2026
  • February 18, 2026
  • January 13, 2026
  • November 5, 2025
  • August 6, 2025

Recent SEC filings

Data status

When each part of this page on Charles River Laboratories was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Charles River Laboratories in brief

What does Charles River Laboratories do?
Charles River Laboratories is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is Charles River Laboratories's stock ticker?
Charles River Laboratories trades under the ticker CRL on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Charles River Laboratories's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Charles River Laboratories reported revenue of $4B, 0.7% lower than a year earlier, according to its SEC filings.
What is Charles River Laboratories's free cash flow?
Charles River Laboratories's free-cash-flow margin is 9.3% of revenue over the trailing twelve months, ranking 17 of the 54 life sciences tools & services companies we cover.
What is Charles River Laboratories's fair value (intrinsic value) per share?
Our discounted-cash-flow model of Charles River Laboratories's free cash flow after stock-based pay gives ~$120 per share in the base case, and ~$73–$170 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Charles River Laboratories's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Blackrock, Inc. and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Charles River Laboratories buying back stock, and does it pay a dividend?
Charles River Laboratories spent $324M on share repurchases over the trailing twelve months, and its diluted share count fell 3.9% over the year.
What is Charles River Laboratories's market cap?
On November 2, 2026, Charles River Laboratories's market capitalisation was about $16.5B and net debt of $2.4B. Market figures come from third-party market data and may be delayed.
How much debt does Charles River Laboratories have?
Charles River Laboratories's debt-to-equity ratio is 92.5%, from its latest balance sheet (105.1% five years earlier). The financial health section below sets out its other solvency checks.
Who are Charles River Laboratories's competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Charles River Laboratories are Mettler Toledo, Illumina, Inc., Bruker Corp, Waters Corporation and Medpace Holdings, Inc. The side-by-side comparison below sets their revenue, margins and growth against Charles River Laboratories's.
Are insiders buying or selling Charles River Laboratories stock?
Over the last 12 months, Charles River Laboratories's directors and officers reported 2 open-market purchases and 21 sales on Form 4. The insider trading page charts every trade.
When is Charles River Laboratories's next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Charles River Laboratories announces its own schedule.